-
Something wrong with this record ?
The bioequivalence of fixed-dose combination tablets of bisoprolol and ramipril and its drug-drug interaction potential
J. Sus, J. Huguet, J. Bosak, B. Setnik, T. Hauser, E. Sicard
Language English Country United States
Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2016
Free Medical Journals
from 2008
PubMed Central
from 2008
Europe PubMed Central
from 2008
ProQuest Central
from 2016-02-01
Open Access Digital Library
from 2008-05-01
Open Access Digital Library
from 2016-01-01
Medline Complete (EBSCOhost)
from 2008-04-01
Health & Medicine (ProQuest)
from 2016-02-01
Wiley-Blackwell Open Access Titles
from 2008
ROAD: Directory of Open Access Scholarly Resources
from 2008
PubMed
34498388
DOI
10.1111/cts.13128
Knihovny.cz E-resources
- MeSH
- Antihypertensive Agents administration & dosage MeSH
- Bisoprolol administration & dosage MeSH
- Adult MeSH
- Drug Therapy, Combination * MeSH
- Drug Interactions * MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Ramipril administration & dosage MeSH
- Therapeutic Equivalency * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
Chronic antihypertensive treatment often includes combination of two or more therapies with complementary mechanism of action targeting different blood pressure (BP) control system. If available, these components are recommended to be administered as a fixed-dose combination (FDC) to reduce tablet burden, improve adherence and thus BP control. A combination of ramipril (RAMI) and bisoprolol (BISO) is one of the options used in clinical practice and is supported by therapeutic guidelines. The clinical program for a novel BISO/RAMI FDC consisted of two randomized, open-label, bioequivalence (BE) studies and one drug-drug interaction (DDI) study. The BE was examined between two FDC strengths of BISO/RAMI (10/10 and 10/5 mg) and the individual reference products administered concomitantly at respective doses after a single oral dose under fasting conditions. In both BE studies, 64 healthy subjects were randomized according to a two-way crossover design. The DDI study evaluated a potential pharmacokinetic (PK) interaction between BISO 10 mg and RAMI 10 mg following their single or concomitant administrations in 30 healthy subjects under fasting condition. BE for BISO/RAMI 10/5 mg and absence of a clinically relevant PK DDI between BISO and RAMI was demonstrated as the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) for area under the concentration time curve (AUC) and maximum concentration (Cmax ) remained within the acceptance range of 80.00 to 125.00%. However, BE for BISO/RAMI 10/10 mg was not demonstrated, as the lower bound of the 90% CI of Cmax for RAMI was outside the acceptance range of BE. Both drugs administered alone or combined were well-tolerated. No PK interaction was observed between BISO and RAMI/ramiprilat, since the co-administration of BISO and RAMI 10 mg single doses resulted in comparable rate and extent of absorption for BISO and RAMI when compared to their individual products.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011441
- 003
- CZ-PrNML
- 005
- 20220506130826.0
- 007
- ta
- 008
- 220425s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/cts.13128 $2 doi
- 035 __
- $a (PubMed)34498388
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Sus, Jan $u Zentiva, k.s., Prague, Czech Republic
- 245 14
- $a The bioequivalence of fixed-dose combination tablets of bisoprolol and ramipril and its drug-drug interaction potential / $c J. Sus, J. Huguet, J. Bosak, B. Setnik, T. Hauser, E. Sicard
- 520 9_
- $a Chronic antihypertensive treatment often includes combination of two or more therapies with complementary mechanism of action targeting different blood pressure (BP) control system. If available, these components are recommended to be administered as a fixed-dose combination (FDC) to reduce tablet burden, improve adherence and thus BP control. A combination of ramipril (RAMI) and bisoprolol (BISO) is one of the options used in clinical practice and is supported by therapeutic guidelines. The clinical program for a novel BISO/RAMI FDC consisted of two randomized, open-label, bioequivalence (BE) studies and one drug-drug interaction (DDI) study. The BE was examined between two FDC strengths of BISO/RAMI (10/10 and 10/5 mg) and the individual reference products administered concomitantly at respective doses after a single oral dose under fasting conditions. In both BE studies, 64 healthy subjects were randomized according to a two-way crossover design. The DDI study evaluated a potential pharmacokinetic (PK) interaction between BISO 10 mg and RAMI 10 mg following their single or concomitant administrations in 30 healthy subjects under fasting condition. BE for BISO/RAMI 10/5 mg and absence of a clinically relevant PK DDI between BISO and RAMI was demonstrated as the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) for area under the concentration time curve (AUC) and maximum concentration (Cmax ) remained within the acceptance range of 80.00 to 125.00%. However, BE for BISO/RAMI 10/10 mg was not demonstrated, as the lower bound of the 90% CI of Cmax for RAMI was outside the acceptance range of BE. Both drugs administered alone or combined were well-tolerated. No PK interaction was observed between BISO and RAMI/ramiprilat, since the co-administration of BISO and RAMI 10 mg single doses resulted in comparable rate and extent of absorption for BISO and RAMI when compared to their individual products.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antihypertenziva $x aplikace a dávkování $7 D000959
- 650 _2
- $a bisoprolol $x aplikace a dávkování $7 D017298
- 650 12
- $a lékové interakce $7 D004347
- 650 12
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a ramipril $x aplikace a dávkování $7 D017257
- 650 12
- $a terapeutická ekvivalence $7 D013810
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Huguet, Jade $u Altasciences, Laval, Quebec, Canada
- 700 1_
- $a Bosak, Jan $u Zentiva, k.s., Prague, Czech Republic
- 700 1_
- $a Setnik, Beatrice $u Altasciences, Laval, Quebec, Canada
- 700 1_
- $a Hauser, Tomas $u Zentiva, k.s., Prague, Czech Republic
- 700 1_
- $a Sicard, Eric $u Altasciences, Laval, Quebec, Canada
- 773 0_
- $w MED00173319 $t Clinical and translational science $x 1752-8062 $g Roč. 15, č. 1 (2022), s. 158-171
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34498388 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130818 $b ABA008
- 999 __
- $a ok $b bmc $g 1789172 $s 1162639
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 15 $c 1 $d 158-171 $e 20210908 $i 1752-8062 $m Clinical and translational science $n Clin Transl Sci $x MED00173319
- LZP __
- $a Pubmed-20220425